Trade Idea: MACK


Good Morning!

Our trade idea from Friday has thus far not provided any upside opportunity.

Technical indicators continue to suggest an increased divergence between the 20 day moving average and present valuations suggestive of increased potential for upside.

Additionally, MACK has a RSI that is potentially extremely undervalued.

It is critical however for MACK to hold its recent low of 1.33. In the event that MACK does not hold this level, it increases the likelihood that we experience more downside before a reversal happens.

As a reminder, when reviewing charts (charting) this does not offer us a full proof advantage in the markets. However, it does provide us with an understanding for potential timing and path of least resistance.

Always protect your downside. If you don’t know how, a good starting place to develop a strategy that works for you is reading my trading guidelines (below).




Good Morning!

Today I would like to bring to your attention a new trade idea, one that I believe offers you a potentially undervalued technical setup.

As a reminder, when reviewing charts (charting) this does not offer us a full proof advantage in the markets. However, it does provide us with an understanding for potential timing and path of least resistance.

Trade Idea: Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK)

Technical Highlights:

  • Last Close: 1.51
    • You need to evaluate the chart in real-time and establish for yourself whether it is an appropriate trade opportunity for you or not.​​​​​​​
  • In late May MACK has experienced a considerable selloff, when it was trading around 3.40 and fell to a low of 1.33 three days ago.
  • MACK has thus far seemingly confirmed this new low, by witnessing higher lows in the past 2 days – a potentially positive indicator.
  • MACK has a 20 day moving average of 2.79, 84% above yesterday’s close.
  • MACK has a RSI of 29 on the daily chart – potentially suggestive of extremely short-term undervaluation.
  • MACK released breaking news yesterday that could prove to be a catalyst for upside (details below).












Recent News:

Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources

CAMBRIDGE, Mass., June 8, 2017 /PRNewswire/ — Merrimack Pharmaceuticals, Inc. (MACK) today announced the expansion of its senior management team through the addition of two new executive hires. Sergio L. Santillana, M.D., MSc, a medical oncologist with extensive industry experience leading a wide range of clinical development programs, has been appointed to the role of Chief Medical Officer, effective June 12, 2017.  In addition, Ellen K. Forest, who served most recently as Director of Human Resources at Baxalta, has joined Merrimack to lead its talent and recruitment strategy as the new Head of Human Resources.

“We are pleased to welcome Sergio and Ellen to Merrimack to help lead our organization in the execution of our refocused research and clinical development strategy,” said Richard Peters, M.D., Ph.D., President and Chief Executive Officer. “The collective expertise of our expanded management team is an invaluable asset to Merrimack as we focus on pinpoint execution across three wholly-owned, innovative and promising clinical-stage programs. With funding into the second half of 2019 to support our corporate objectives, a refined strategic focus and experienced teams in place to execute, we are poised to deliver on the long-term potential of our pipeline for cancer patients and our shareholders.”

Source: Yahoo Finance

Company Highlights:

Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives.

Its mission is to transform cancer care through the smart design and development of targeted solutions based on the deep understanding of cancer pathways and biological markers.

All of Merrimack’s product candidates, including three in clinical studies and several others in preclinical development, fit into its strategy of 1) understanding the biological problems it is trying to solve, 2) designing specific solutions and 3) developing those solutions for biomarker-selected patients.

This three-pronged strategy seeks to ensure optimal patient outcomes.

Source: Yahoo Finance

If you are not familiar with my trading guidelines, please read them below. These trading guidelines are designed to give you a starting point to develop your own personal trading philosophy and approach.

Since every traders/investors circumstance is different, make sure you create a personalized approach that works for you and always consult a financial adviser (not me).

Happy Trading!

Ultimate Stock Alerts 


Trading Rules [Please Review Before Taking Any Action]:

  1. Do not invest more than you are willing to lose. No one likes to consider the worst case, but it’s always a risk that exists. Rule of thumb – if you cannot sleep at night as a consequence of your investment, then you have over invested.
  2. Keep calm. Do not chase. Decide for yourself if you like the trade. If you are not comfortable with the perceived risks, stay out. Timelines are to be decided by you. Approach methodically, and seek technical confirmation for direction. Always trade with a strategy in mind.
  3. Never use market orders. Only use buy and sell limit orders. Protecting your investment is more important than missing gains. Use “trailing stop %” or “trailing stop limit” orders. Personally I prefer mental stops while actively managing trades rather than entering your stop into your brokerage account.
  4. Cut losses quickly when day/swing trading. It’s better to acknowledge being wrong than to have false hope. Sometimes you will be wrong in doing so, often times it will save you. It all depends on your entry.
  5. Actively manage all your investments & trade during market hours only. Trading during pre/post market hours carries greater volatility/risk.


This report/release is a commercial advertisement and is for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for compensation. Never invest in any stock featured on our reports/releases unless you can afford to lose your entire investment. The track record, gains, upside or losses are all hypothetical and should not be considered as a basis for investment.

This report/release is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the States or other jurisdictions in which the security is eligible for sale. Reports/releases distributed through disseminated reports/released are not disclosure documents. If you are considering purchasing any securities of an advertised company, you should read and review, if and to the extent available, any information concerning a marketed company available at the web sites of the U.S. Securities and Exchange Commission (the “SEC”) at;the Financial Industry Regulatory Authority (the “FINRA”) at and your State Securities Administrator. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. You are responsible for verifying all claims and conducting your own due diligence.

You agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in our disseminated reports/releases is provided only for your reference and convenience. We are not responsible for the accuracy or reliability of these external sites, nor are we responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on us, and we are not liable for, any actions taken by you based on any information contained in any disseminated report/release or hyperlink. You also acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser. You acknowledge that you will consult with your own advisers regarding any decisions as to any company mentioned herein.

We have not determined if the statements and opinions of the message are accurate, correct or truthful. The profiles we publish are compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because virtually all information relied upon by us in preparing an Issuer profile comes from a public source which has been made public directly from the Issuer, the information is not confirmed with a second source.

The purpose of this report/release, like any promotion, is to provide publicity for the client company, its products or services. Owners and operators of have not been compensated nor expect to receive any compensation for distribution of our opinions and publicly available information for MACK as of 06/13/17. Owners and operators of do not own any equity nor debt in MACK as of 6/13/17. You should not rely on the information presented; you should do independent research to form your own opinion and decision. Information contained in our disseminated reports/releases does not constitute investment, legal or tax advice upon which you should rely. The purchase of high-risk securities may result in the loss of your entire investment. Owners and operators of own several newsletters, therefore you may receive our emails featuring companies at different times.

You are receiving this report/release because you subscribed to received it at our website or through a third party site.  All of our newsletters include an “unsubscribe” link, and you can remove yourself at any time from our newsletters by clicking on that “unsubscribe” link. You can also contact us at to change your information at any time.  By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer which can be read at any time at

Full disclaimer can be read at

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

Leave a Reply

Your email address will not be published. Required fields are marked *


Free Guide To Become A Successful Trader/Investor

lock We Never Sell Or Share Your Email

No Hidden Fees. Unsubscribe Anytime.